# Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer

> **NCT04921527** · PHASE3 · RECRUITING · sponsor: **Chipscreen Biosciences, Ltd.** · enrollment: 454 (estimated)

## Conditions studied

- Ovarian Cancer
- Relapsed or Refractory
- Chiauranib
- Paclitaxel

## Interventions

- **DRUG:** chiauranib
- **DRUG:** Placebo
- **DRUG:** Paclitaxel

## Key facts

- **NCT ID:** NCT04921527
- **Lead sponsor:** Chipscreen Biosciences, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-12-20
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 454 (ESTIMATED)
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04921527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04921527, "Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT04921527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*